Breaking News Instant updates and real-time market news.

Nabriva Therapeutics to host special shareholder meeting

Special Shareholder Meeting will be held in Dublin, Ireland on September 15 at 10 am.

15

Sep

25

Sep

NBRVNabriva Therapeutics

$8.48

-0.02 (-0.24%)

08/25/17

RHCO

08/25/17INITIATIONRHCOBuy

Nabriva Therapeutics initiated with a Buy at SunTrust

SunTrust analyst Edward Nash started coverage of Nabriva Therapeutics with a $20 price target and a Buy rating. The analyst says that the company's antibiotic, Lefamulin, is "a late stage asset targeting a sizeable market." He says that the drug targets a U.S. incidence rate of more than 5M and he estimates that it can achieve worldwide sales of over $700M.

Leerink analyst Paul Matteis raised his price target for Nabriva Therapeutics to $20 from $14 ahead of Phase 3 results in 2H17. His analysis of in vitro, pharmacokinetic, drug distribution, safety and skin efficacy data render the analyst optimistic that Phase 3 trials have reasonable odds of success, creating what he views as a favorable risk/reward for the stock. Matteis reiterates an Outperform rating on the shares.

RBC Capital analyst Adnan Butt says that Nabriva's stock is "undervalued based on numerous data points." The analyst thinks that the stock should rise significantly when data for the company's antibiotic lefamulin is released in 2H17. Butt expects the data from the trial to be positive, and he keeps a $22 price target and an Outperform rating on the stock.

UP AFTER EARNINGS: Cintas (CTAS), up 2.9%... Micron (MU), up 2.8%. ALSO HIGHER: Editas Medicine (EDIT), up 3.1% after it received the EMA's orphan medicinal product designation for EDIT-101... Twitter (TWTR), up 1.8% after it said it will start testing longer, 280-character tweets with a small group. DOWN AFTER EARNINGS: Nike (NKE), down 3.2%. ALSO LOWER: Kornit Digital (KRNT), down 12.2% after it cut its third quarter revenue guidance... Westlake Chemical Partners (WLKP), down 8.3% after it filed to sell 4.5M units for limited partners... Intra-Cellular (ITCI), down 7.2% after it filed to sell $150M in common stock... Ascendis Pharma (ASND), down 4.3% after it announced an offering of $125M of ADSs.